Cargando…
A Minimalist Strategy Towards Temporarily Defining Protection for COVID-19
Until either efficacious therapy or vaccination for COVID-19 is achieved, there will be a need to regain world economic stability while yet controlling the pandemic with current approaches. For those infected thus far, there is a prevailing perspective that devising recognition for protective immuni...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7501512/ https://www.ncbi.nlm.nih.gov/pubmed/32984765 http://dx.doi.org/10.1007/s42399-020-00533-4 |
_version_ | 1783584041775136768 |
---|---|
author | Cimolai, Nevio |
author_facet | Cimolai, Nevio |
author_sort | Cimolai, Nevio |
collection | PubMed |
description | Until either efficacious therapy or vaccination for COVID-19 is achieved, there will be a need to regain world economic stability while yet controlling the pandemic with current approaches. For those infected thus far, there is a prevailing perspective that devising recognition for protective immunity will progressively allow segments of society to return to some functionality more than is existing. At this time, the best correlates with protection from natural coronavirus infections are systemic neutralizing antibody and mucosal IgA. Serum neutralizing antibody more easily fulfills the latter requisite, but current live virus methods for neutralization prevent large-scale application. It is conceivable that the exposure of previously infected individuals can allow for the definition of protective thresholds of neutralizing antibody. Thereafter, many other antibody assays will be able to screen for surrogate protection after correlations with protective neutralizing antibody are made. Specificity of common antibody tests would benefit from confirmatory blocking systems or confirmatory immunoblotting fingerprints with well-defined antigen(s). The opportunity for the scientific community to make these assessments is evident in the current context of the COVID-19 epidemic given the large numbers of infected individuals worldwide. Such information will also be vital to guide vaccine development and/or immunotherapy. |
format | Online Article Text |
id | pubmed-7501512 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-75015122020-09-21 A Minimalist Strategy Towards Temporarily Defining Protection for COVID-19 Cimolai, Nevio SN Compr Clin Med Covid-19 Until either efficacious therapy or vaccination for COVID-19 is achieved, there will be a need to regain world economic stability while yet controlling the pandemic with current approaches. For those infected thus far, there is a prevailing perspective that devising recognition for protective immunity will progressively allow segments of society to return to some functionality more than is existing. At this time, the best correlates with protection from natural coronavirus infections are systemic neutralizing antibody and mucosal IgA. Serum neutralizing antibody more easily fulfills the latter requisite, but current live virus methods for neutralization prevent large-scale application. It is conceivable that the exposure of previously infected individuals can allow for the definition of protective thresholds of neutralizing antibody. Thereafter, many other antibody assays will be able to screen for surrogate protection after correlations with protective neutralizing antibody are made. Specificity of common antibody tests would benefit from confirmatory blocking systems or confirmatory immunoblotting fingerprints with well-defined antigen(s). The opportunity for the scientific community to make these assessments is evident in the current context of the COVID-19 epidemic given the large numbers of infected individuals worldwide. Such information will also be vital to guide vaccine development and/or immunotherapy. Springer International Publishing 2020-09-19 2020 /pmc/articles/PMC7501512/ /pubmed/32984765 http://dx.doi.org/10.1007/s42399-020-00533-4 Text en © Springer Nature Switzerland AG 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Covid-19 Cimolai, Nevio A Minimalist Strategy Towards Temporarily Defining Protection for COVID-19 |
title | A Minimalist Strategy Towards Temporarily Defining Protection for COVID-19 |
title_full | A Minimalist Strategy Towards Temporarily Defining Protection for COVID-19 |
title_fullStr | A Minimalist Strategy Towards Temporarily Defining Protection for COVID-19 |
title_full_unstemmed | A Minimalist Strategy Towards Temporarily Defining Protection for COVID-19 |
title_short | A Minimalist Strategy Towards Temporarily Defining Protection for COVID-19 |
title_sort | minimalist strategy towards temporarily defining protection for covid-19 |
topic | Covid-19 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7501512/ https://www.ncbi.nlm.nih.gov/pubmed/32984765 http://dx.doi.org/10.1007/s42399-020-00533-4 |
work_keys_str_mv | AT cimolainevio aminimaliststrategytowardstemporarilydefiningprotectionforcovid19 AT cimolainevio minimaliststrategytowardstemporarilydefiningprotectionforcovid19 |